Cansino Biologics, Inc. Class ASSE: 688185

Announcement on Voluntary Disclosure of the Initiation of Phase I Clinical Trial of the Adsorbed Acellular Pertussis (Component), Diphtheria and Tetanus, Haemophilus influenzae Type b (Conjugate) – Meningococcal ACYW-135 (Conjugate) Combination Vaccine and the Completion of Enrollment of the First Subject

· Issued by Cansino Biologics, Inc. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of the Initiation of Phase I Clinical Trial of the Adsorbed Acellular Pertussis (Component), Diphtheria and Tetanus, Haemophilus influenzae Type b (Conjugate) – Meningococcal ACYW-135 (Conjugate) Combination Vaccine and the Completion of Enrollment of the First Subject

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis